Skip to main content
Insitro logo

Insitro

Updated Mar 24, 2026

How Insitro stacks up in AI Healthcare — funding data, key investors, and more.

🇺🇸United StatesSeries CAI Healthcare

Out of 100

🇺🇸

HQ

United States

🗓

Founded

2018

💰

Raised

$743M

🏷️

Stage

Series C

👥

Team

300

Insitro is an AI-driven drug discovery company founded in 2018 that applies machine learning to accelerate pharmaceutical development. The company combines computational biology, artificial intelligence, and wet-lab experimentation to identify and validate drug targets more efficiently than traditional methods. Insitro's platform uses proprietary algorithms to analyze complex biological data,

Is this your company? Claim it →

Key Facts

  • Insitro is valued at $2.2B as of March 2026.
  • Insitro has raised a total of $743M in disclosed funding across 3 funding rounds.
  • Insitro was founded in 2018 by Daphne Koller and is headquartered in United States.
  • Insitro employs approximately 300 people.
  • Insitro operates in the AI Healthcare category and is currently at the Series C stage.
  • Insitro has an Awaira Score of 73/100, ranking it among the tracked AI companies on Awaira.
  • Insitro's most recent funding round was a Series C of $200M closed in October 2021, led by Andreessen Horowitz.

Source: Awaira · Updated Mar 24, 2026

$2.2B

Post-money

$743M

All rounds

73/100

2018

300 employees

Strengths

Unicorn status with $2.2B valuation

Strong Awaira Score of 73/100

Growing team of 300 employees

Analysis based on publicly available data. Not investment advice.

3

Total Rounds

$124.33M

Avg Round Size

2.8yr

Funding Span

Insitro raised 3 rounds over 2.8 years, averaging $124.33M per round — a pace of roughly one round every 11 months.

⚠️ ESTIMATE
💵Est. Annual Revenue
$50M–$500M estimated ARR

Awaira estimate based on public data. Not financial advice.

How does Insitro stack up against competitors?

MetricInsitroButterfly NetworkTempusAlan
Awaira Score73/10085/10084/10083/100
Total Raised$743M$370M$1.05B$750M
Valuation$2.2B$957M$8.1B$5.83B
StageSeries CPublicPublicSeries D
Founded2018201120152016
Employees300500-10002500500-1000
Country🇺🇸🇺🇸🇺🇸🇫🇷
D

Daphne Koller

Founder & CEO

View founder profile →
StageSeries C
Employees300
Country🇺🇸 United States
Connect
Inactive
3 rounds
Series CLatest

Led by Andreessen Horowitz

$200M

Oct 2021

Series B

Led by Andreessen Horowitz

$143M

Jan 2020

Series A

Led by Andreessen Horowitz

$30M

Jan 2019

Frequently Asked Questions

What is Insitro's valuation?
The current market valuation is approximately $2.2B, based on publicly available funding data.
Who invested in Insitro?
On the cap table: Andreessen Horowitz, Casdin Partners, Boehringer Ingelheim, Salesforce Ventures. Their combined backing has helped fund operations and expansion.
When did Insitro last raise funding?
Capital was most recently raised through a Series C of $200M in October 2021. The round was led by Andreessen Horowitz.
How many employees does Insitro have?
The team is roughly 300 people, headquartered in United States.
What does Insitro do?
Insitro is an AI-driven drug discovery company founded in 2018 that applies machine learning to accelerate pharmaceutical development. The company combines computational biology, artificial intelligence, and wet-lab experimentation to identify and validate drug targets more efficiently than traditional methods. The company operates in the AI Healthcare sector from United States.
Who founded Insitro?
Behind the company is Daphne Koller, who got it off the ground in 2018 in United States. Daphne Koller serves as Founder & CEO.
Is Insitro profitable?
Whether the company is profitable hasn't been confirmed publicly. It has raised $743M in total funding and is classified at the Series C stage.
Where is Insitro headquartered?
Home base is United States 🇺🇸. The AI Healthcare company was founded in 2018 and operates from there.
⚔️

Compare Insitro

See how Insitro stacks up against competitors in valuation, funding, team size, and Awaira Score.

Browse all comparisons →